Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2000
05/18/2000WO2000028001A1 Modified exosomes and uses
05/18/2000WO2000027887A2 Cross-linked hyaluronic acids and medical uses thereof
05/18/2000WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
05/18/2000WO2000027874A2 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
05/18/2000WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use
05/18/2000WO2000027864A1 CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE
05/18/2000WO2000027857A2 Novel erythromycin derivatives, preparation method and use as medicines
05/18/2000WO2000027851A1 Novel type condensed pyridazinone compounds
05/18/2000WO2000027850A2 Crf receptor antagonists and methods relating thereto
05/18/2000WO2000027849A2 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
05/18/2000WO2000027848A1 Pyrazolopyrimidinone derivatives for the treatment of impotence
05/18/2000WO2000027846A2 Crf receptor antagonists and methods relating thereto
05/18/2000WO2000027845A1 Spiro-indolines as y5 receptor antagonists
05/18/2000WO2000027842A1 Compounds
05/18/2000WO2000027832A2 Thiazole derivatives as ppar gamma ligands
05/18/2000WO2000027830A1 Thiocarbamic acid derivatives
05/18/2000WO2000027828A2 2,4-disubstituted triazine derivatives with anti hiv activity
05/18/2000WO2000027826A1 Novel pyrimidines, the production thereof and their use
05/18/2000WO2000027825A1 Hiv replication inhibiting pyrimidines
05/18/2000WO2000027823A1 Gastrin and cholecystokinin receptor ligands
05/18/2000WO2000027822A2 Tricyclic pyrazole derivatives
05/18/2000WO2000027820A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors
05/18/2000WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments
05/18/2000WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands
05/18/2000WO2000027814A1 Avidin derivatives and uses thereof
05/18/2000WO2000027811A1 Neurotrophic diamide and carbamate agents
05/18/2000WO2000027808A1 N-arylsulfonyl amino acid omega amides
05/18/2000WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use
05/18/2000WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
05/18/2000WO2000027799A1 New esters derived from substituted phenyl-cyclohexyl compounds
05/18/2000WO2000027795A1 Transfection reagents
05/18/2000WO2000027792A1 Novel compounds and medicinal use thereof
05/18/2000WO2000027434A1 Combinations comprising a beta-agonist and a further antidiabetic agent
05/18/2000WO2000027428A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
05/18/2000WO2000027424A2 Upregulation of endogenous prostaglandins to lower intraocular pressure
05/18/2000WO2000027423A2 Methods and compositions for treating common cold symptoms
05/18/2000WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies
05/18/2000WO2000027418A2 A method for treating tissue damaged from ischemia
05/18/2000WO2000027416A1 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway
05/18/2000WO2000027414A2 Inhibition of the formation of vascular hyperpermeability
05/18/2000WO2000027405A1 Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same
05/18/2000WO2000027404A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic
05/18/2000WO2000027403A1 Method for treating a patient with neoplasia by treatment with a pyrimidine analog
05/18/2000WO2000027401A1 Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
05/18/2000WO2000027400A1 Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions
05/18/2000WO2000027399A1 Method for preventing scar tissue formation
05/18/2000WO2000027398A1 Pharmaceutical moxifloxacin preparation
05/18/2000WO2000027397A1 Antihypertensive medicaments containing lacidipine and telmisartan
05/18/2000WO2000027396A1 Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
05/18/2000WO2000027395A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
05/18/2000WO2000027394A1 Activators of soluble guanylate cyclase
05/18/2000WO2000027393A1 Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same
05/18/2000WO2000027392A1 Chromone enteric release formulation
05/18/2000WO2000027391A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex
05/18/2000WO2000027390A1 Ionic silver complex
05/18/2000WO2000027389A1 Oxy-vanadium (iv) complexes having spermicidal activity
05/18/2000WO2000027388A1 Glucose and lipid lowering compounds
05/18/2000WO2000027387A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
05/18/2000WO2000027386A1 Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
05/18/2000WO2000027385A1 Dispersible compositions containing l-dopa ethyl ester
05/18/2000WO2000027384A1 METHOD FOR AUGMENTING THE INOTROPIC EFFECTS OF β-ADRENERGIC AGONISTS USING PYRUVATE THERAPY
05/18/2000WO2000027383A1 Dysuria remedies
05/18/2000WO2000027382A2 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
05/18/2000WO2000027381A2 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
05/18/2000WO2000027380A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
05/18/2000WO2000027379A2 Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
05/18/2000WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
05/18/2000WO2000027376A2 Use of thiol compounds, oxidoreductases and/or hydrolases for the treatment of tinnitus, especially chronic tinnitus
05/18/2000WO2000027375A2 Idarubicin plus melphalan conditioning regimen
05/18/2000WO2000027374A2 The use of excitatory amino acid transporter inhibitors to reduce cns white matter injury
05/18/2000WO2000027373A1 Dry powder pharmaceutical formulation
05/18/2000WO2000027372A1 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
05/18/2000WO2000027371A1 Composition for the transdermal delivery of lerisetron
05/18/2000WO2000027370A1 Controlled release formulation for water soluble drugs
05/18/2000WO2000027369A1 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
05/18/2000WO2000027368A1 Particles coated with granulated crystalline ibuprofen
05/18/2000WO2000027366A1 Pharmaceutical formulation comprising omeprazole
05/18/2000WO2000027364A1 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
05/18/2000WO2000027363A1 Aerosols comprising nanoparticle drugs
05/18/2000WO2000027362A1 Method of producing vitamin powders
05/18/2000WO2000027359A1 An inhalation system
05/18/2000WO2000027357A1 Improved fast disintegrating tablet
05/18/2000WO2000027352A1 Topical compositions containing whey proteins
05/18/2000WO2000027341A2 Novel method of treatment
05/18/2000WO2000027327A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis
05/18/2000WO2000027204A1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
05/18/2000WO2000027196A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
05/18/2000WO2000027194A1 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
05/18/2000WO2000027191A1 Disposable premoistened wipe containing an antimicrobial protease inhibitor
05/18/2000WO2000010553A3 Carbamate and urea compositions and neurotrophic uses
05/18/2000WO2000010544A3 A method for preventing the onset of asthma
05/18/2000WO2000009734A3 Methods and compositions for use in spliceosome mediated rna trans-splicing
05/18/2000WO2000009672A9 Dnazymes and methods for treating restenosis
05/18/2000WO2000009479A3 Heterocyclic thioesters or ketones for vision and memory disorders
05/18/2000WO2000009139A3 Methods for promoting survival of myelin producing cells
05/18/2000WO2000009137A3 Aminosterol compounds and uses thereof
05/18/2000WO2000009130A3 New pharmaceutical uses for nos inhibitors
05/18/2000WO2000009108A3 Compositions and uses for vision and memory disorders
05/18/2000WO2000009098A3 Method for treating ocular neovascular diseases
05/18/2000WO2000009097A3 Pharmaceutical composition with antitumor activity on the basis of carboplatin
1 ... 6315 6316 6317 6318 6319 6320 6321 6322 6323 6324 6325 6326 6327 6328 6329 6330 6331 6332 6333 6334 6335 ... 7860